Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04790513 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients
A Phase 3 study, sponsored by LIB Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 204
- Enrollment target
NCT04790513: Completed Phase 3 study, sponsored by LIB Therapeutics.
NCT04790513 is a Phase 3 study that has completed, run by LIB Therapeutics. The registered enrollment target is 204 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04790513, a Phase 3 study, has completed, sponsored by LIB Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 204 participants
- Enrollment target
Study Summary
Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and other LDL-C-lowering drug therapy.
Primary Outcome
LS Mean percent change from baseline to week 12
Interventions
- BIOLOGICAL alirocumab
- BIOLOGICAL lerodalcibep
- BIOLOGICAL evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-04-22 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 3 |
What the finished NCT04790513 record still lists
NCT04790513 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 3 interventions - of which alirocumab is the first listed.
NCT04790513 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04790513 about?
NCT04790513 is a clinical study titled "Trial to Evaluate Efficacy and Safety of LIB003, Evolocumab and Alirocumab in High-risk CVD Patients". Comparison of LDL-C reductions at Week 12 of monthly (Q4W\[≤ 31 days\]) dosing of LIB003 300 mg administered subcutaneously (SC) to Q4W dosing of evolocumab (Repatha) 420 mg and alirocumab (Praluent) 300 mg in patients with CVD or at high risk for CVD on a stable diet and high intensity statin and o...
What is the current status of trial NCT04790513?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 204 participants. The study started on 2021-04-22. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT04790513?
The interventions under investigation include: alirocumab (BIOLOGICAL), lerodalcibep (BIOLOGICAL), evolocumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04790513?
This trial is sponsored by LIB Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04790513's enrollment target sits among peer trials
204 1352nd of 2000 higher than 649 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI